Your browser is no longer supported. Please, upgrade your browser.
Acorda Therapeutics, Inc.
Index- P/E1.18 EPS (ttm)5.32 Insider Own1.30% Shs Outstand47.71M Perf Week-0.63%
Market Cap62.02M Forward P/E- EPS next Y-10.35 Insider Trans0.00% Shs Float9.35M Perf Month-6.68%
Income49.10M PEG0.04 EPS next Q-1.48 Inst Own25.70% Short Float8.02% Perf Quarter56.98%
Sales165.30M P/S0.38 EPS this Y23.40% Inst Trans-39.10% Short Ratio0.67 Perf Half Y88.45%
Book/sh6.57 P/B0.96 EPS next Y-30.80% ROA6.60% Target Price- Perf Year-14.77%
Cash/sh6.41 P/C0.98 EPS next 5Y29.00% ROE16.10% 52W Range2.53 - 9.84 Perf YTD51.91%
Dividend- P/FCF- EPS past 5Y16.45% ROI-48.20% 52W High-36.08% Beta0.56
Dividend %- Quick Ratio0.90 Sales past 5Y-13.70% Gross Margin81.00% 52W Low148.18% ATR0.53
Employees344 Current Ratio1.10 Sales Q/Q11.30% Oper. Margin42.30% RSI (14)46.21 Volatility7.47% 7.34%
OptionableYes Debt/Eq0.73 EPS Q/Q100.10% Profit Margin29.70% Rel Volume0.20 Prev Close6.19
ShortableYes LT Debt/Eq0.52 EarningsMar 04 AMC Payout0.00% Avg Volume1.12M Price6.29
Recom3.00 SMA20-9.03% SMA504.00% SMA20032.47% Volume226,640 Change1.62%
Aug-14-19Downgrade H.C. Wainwright Buy → Neutral $31 → $6
May-23-19Initiated Wedbush Neutral
Dec-11-18Downgrade Goldman Neutral → Sell
Aug-07-18Reiterated Stifel Hold $15 → $25
Feb-16-18Upgrade Piper Jaffray Neutral → Overweight
Jan-17-18Reiterated H.C. Wainwright Buy $34 → $31
Nov-28-17Resumed Piper Jaffray Neutral $22
Nov-16-17Downgrade Stifel Buy → Hold $26 → $15
Nov-16-17Downgrade Raymond James Mkt Perform → Underperform
Nov-09-17Initiated Oppenheimer Perform
Nov-08-17Initiated H.C. Wainwright Buy $35
Oct-06-17Resumed Goldman Sell $20
Jul-11-17Initiated Jefferies Hold
Apr-03-17Downgrade JP Morgan Overweight → Neutral
Feb-15-17Upgrade Goldman Sell → Neutral
Nov-30-16Upgrade JP Morgan Neutral → Overweight
Oct-04-16Resumed Leerink Partners Mkt Perform $25
Mar-30-16Initiated Goldman Sell
Sep-01-15Initiated Raymond James Mkt Perform
Jun-09-15Initiated Guggenheim Neutral
Mar-03-21 12:52PM  
Mar-02-21 08:43AM  
Feb-26-21 10:10AM  
Feb-25-21 07:00AM  
Feb-19-21 07:00AM  
Feb-11-21 11:12AM  
Feb-10-21 10:21AM  
Feb-08-21 12:40PM  
Feb-04-21 11:48AM  
Feb-02-21 03:23PM  
Feb-01-21 10:28AM  
Jan-28-21 10:12AM  
Jan-27-21 11:13AM  
Jan-25-21 09:28AM  
Jan-22-21 09:02AM  
Jan-21-21 12:16PM  
Jan-20-21 12:18PM  
Jan-15-21 08:19PM  
Jan-14-21 12:34PM  
Jan-13-21 07:25AM  
Jan-12-21 04:07PM  
Jan-11-21 04:20PM  
Dec-31-20 04:19PM  
Dec-21-20 12:00PM  
Dec-07-20 10:22PM  
Dec-03-20 08:53AM  
Nov-23-20 10:24AM  
Nov-16-20 09:48AM  
Nov-08-20 07:07AM  
Nov-03-20 05:15PM  
Nov-02-20 10:17AM  
Oct-27-20 07:00AM  
Oct-26-20 12:31PM  
Oct-20-20 11:17AM  
Sep-29-20 11:25AM  
Sep-17-20 07:00AM  
Aug-04-20 06:15PM  
Jul-31-20 12:45PM  
Jul-28-20 07:00AM  
Jul-08-20 06:40PM  
Jun-16-20 04:46PM  
Jun-12-20 09:36AM  
Jun-09-20 10:01AM  
Jun-04-20 11:31AM  
Jun-03-20 09:05AM  
May-06-20 07:23PM  
May-05-20 06:15PM  
Apr-28-20 07:00AM  
Apr-24-20 11:49AM  
Apr-16-20 05:45PM  
Apr-07-20 05:50PM  
Apr-03-20 08:31AM  
Apr-02-20 10:08AM  
Mar-30-20 08:06AM  
Mar-17-20 12:00PM  
Mar-14-20 11:30AM  
Feb-24-20 07:00AM  
Feb-18-20 01:44AM  
Feb-14-20 11:57AM  
Feb-13-20 10:25AM  
Feb-10-20 10:20AM  
Feb-06-20 12:31PM  
Jan-30-20 07:00AM  
Jan-24-20 08:54AM  
Jan-15-20 07:00AM  
Jan-08-20 07:00AM  
Jan-07-20 10:55AM  
Jan-03-20 07:55AM  
Dec-26-19 07:00AM  
Dec-23-19 05:30AM  
Dec-12-19 10:31AM  
Dec-04-19 11:30AM  
Dec-02-19 10:22AM  
Nov-27-19 07:00AM  
Nov-12-19 07:00AM  
Nov-08-19 10:21AM  
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease and ARCUS product for the treatment of acute migraine. Further, it develops rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.